Replies to post #15696 on Marker Therapeutics Inc (MRKR)

[erg61]

Starting to get a lot of exposer:

http://www.keyc.com/story/31817707/astrazeneca-beefs-up-immuno-oncology-pipeline-with-tapimmune-technology

Keyc News 12 CBS & Fox

TapImmune has much more to offer than TPIV 200 for ovarian cancer. TPIV 200 is also in a U.S. Department of Defense funded Phase 2 trial for triple negative breast cancer at the world renowned Mayo Clinic. TPIV 100 is headed into Phase 2 for HER2/neu breast cancer. The company’s preclinical pipeline also holds promise for some very innovative new vaccines.

Big pharma tapping into TapImmune as an acquisition candidate is likely. Merck Research Laboratories’
Vice President and Therapeutic Area Head of Oncology Early Stage Development, Eric Rubin stated Merck is “scouring the world, looking for immunomodulatory agents.” Based on recent M&A activity, Merck is not alone.

http://www.europeanpharmaceuticalreview.com/40636/news/industry-news/tpiv-200-durvalumab-ovarian-cancer/

TPIV 200 and durvalumab to be evaluated in a Phase II ovarian cancer study